The Role of High-Density Lipoprotein in COVID-19

Frontiers in Pharmacology

Yanjun Zhong¹  Jinxiu Li¹  Haiyun Dong¹  Jiayi Deng¹  Guyi Wang¹  Chenfang Wu¹  Shangjie Wu² 

[1] Department of Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China;Department of Respiratory, The Second Xiangya Hospital, Central South University, Changsha, China;

关键词: COVID-19;    SARS-CoV-2;    lipoproteins;    HDL;    angiotensin-converting enzyme 2;   

DOI  :  10.3389/fphar.2021.720283

来源: DOAJ

【 摘 要 】

The current Coronavirus disease 2019 (COVID-19) pandemic has become a global challenge. Managing a large number of acutely ill patients in a short time, whilst reducing the fatality rate and dealing with complications, brings unique difficulties. The most striking pathophysiological features of patients with severe COVID-19 are dysregulated immune responses and abnormal coagulation function, which can result in multiple-organ failure and death. Normally metabolized high-density lipoprotein (HDL) performs several functions, including reverse cholesterol transport, direct binding to lipopolysaccharide (LPS) to neutralize LPS activity, regulation of inflammatory response, anti-thrombotic effects, antioxidant, and anti-apoptotic properties. Clinical data shows that significantly decreased HDL levels in patients with COVID-19 are correlated with both disease severity and mortality. However, the role of HDL in COVID-19 and its specific mechanism remain unclear. In this analysis, we review current evidence mainly in the following areas: firstly, the pathophysiological characteristics of COVID-19, secondly, the pleiotropic properties of HDL, thirdly, the changes and clinical significance of HDL in COVID-19, and fourthly the prospect of HDL-targeting therapy in COVID-19 to clarify the role of HDL in the pathogenesis of COVID-19 and discuss the potential of HDL therapy in COVID-19.

【 授权许可】

Unknown